Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects three bowel cancer drugs

The National Institute for Health and Clinical Excellence (NICE) has decided to not recommend three metastatic colorectal cancer drugs as they are not deemed cost effective

The National Institute for Health and Clinical Excellence (NICE) has rejected three drugs for the treatment of metastatic colorectal cancer, as they do not represent value for money.

NICE decided not to recommend Roche's Avastin, Merck KGaA's Erbitux and Amgen's Vectibix, as the high cost of the drugs could not be justified. The agency said that no convincing data was presented to demonstrate the extension of life for a patient with the disease.

NICE has currently recommended six treatments for the various stages of colorectal cancer, and commented that it was “disappointed not to be able to recommend” the three drugs.

Around 20-55 per cent of people with colorectal cancer have metastatic disease by the time of diagnosis.

The companies have been allowed to submit further comments on the committee's interpretation of their products, or consider reducing their prices.

5th September 2011

From: Healthcare

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments....
Keith Berelowitz
Transforming clinical trials to accelerate drug development
...
How the WHO hepatitis strategy measures up in the field
With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...